LONDON, May 10, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2023, and recent business highlights.
“We continue to make progress in our ongoing Phase I/IIa clinical trials evaluating our clonal neoantigen-reactive T cell (cNeT) therapy for the treatment of advanced NSCLC (CHIRON) and metastatic malignant melanoma (THETIS). Additionally, we continue to further develop PELEUS™, our patented AI-driven bioinformatics platform, that uses multi-region sequencing analysis to provide what we believe is the best method to accurately identify clonal neoantigens,” said Dr Iraj Ali, Chief Executive Officer of Achilles Therapeutics. “We are excited about the new AI immunogenicity prediction capability of the PELEUS™ platform and are very pleased with the recent grants of a US patent and MHRA Innovation Passport. We look forward to sharing more about the PELEUS™ platform at an upcoming scientific meeting and reporting additional clinical and translational science data in the fourth quarter of this year, which builds on the encouraging clinical results observed so far.”
Business Highlights
Financial Highlights
2023 Focus
About Achilles Therapeutics
Achilles is a clinical-stage biopharmaceutical company developing AI-Powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.
About Innovation Passport and ILAP
ILAP was launched by the MHRA in January 2021 with an aim to accelerate the development of and facilitate patient access to medicines. The Innovation Passport is granted by the UK's ILAP Steering Group, which consists of representatives from MHRA, the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), the All Wales Therapeutics and Toxicology Centre (AWTTC) and the National Health Service (NHS) England. It is the first step in the ILAP process and awarded to companies developing therapies with the potential to offer significant benefit to patients who have conditions that are life-threatening or seriously debilitating. Additional information is available on the UK government website.
Forward Looking Statements
This press release contains express or implied forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Investors:
Meru Advisors
Lee M. Stern
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
+44 (0) 203 709 5000
This email address is being protected from spambots. You need JavaScript enabled to view it.
ACHILLES THERAPEUTICS PLC
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except share and per share amounts)
(expressed in U.S. Dollars, unless otherwise stated)
| March 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 158,460 | $ | 173,338 | ||||
| Prepaid expenses and other current assets | 26,802 | 23,242 | ||||||
| Total current assets | 185,262 | 196,580 | ||||||
| Non-current assets: | ||||||||
| Property and equipment, net | 11,800 | 12,399 | ||||||
| Operating lease right of use assets | 7,216 | 8,081 | ||||||
| Deferred tax assets | 185 | 251 | ||||||
| Restricted cash | 33 | 33 | ||||||
| Other assets | 3,139 | 3,014 | ||||||
| Total non-current assets | 22,373 | 23,778 | ||||||
| TOTAL ASSETS | $ | 207,635 | $ | 220,358 | ||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 7,650 | $ | 5,187 | ||||
| Income taxes payable | 304 | 326 | ||||||
| Accrued expenses and other liabilities | 5,955 | 8,292 | ||||||
| Operating lease liabilities-current | 4,038 | 4,188 | ||||||
| Total current liabilities | 17,947 | 17,993 | ||||||
| Non-current liabilities: | ||||||||
| Operating lease liabilities-non-current | 3,563 | 4,388 | ||||||
| Other long-term liability | 954 | 933 | ||||||
| Total non-current liabilities | 4,517 | 5,321 | ||||||
| Total liabilities | 22,464 | 23,314 | ||||||
| Commitments and contingencies | ||||||||
| Shareholders’ equity: | ||||||||
| Ordinary shares, £0.001 par value; 40,938,453 and 40,932,727 shares authorized, issued and outstanding at March 31, 2023 and December 31, 2022, respectively | 54 | 54 | ||||||
| Deferred shares, £92,451.851 par value, one share authorized, issued and outstanding at March 31, 2023 and December 31, 2022 | 128 | 128 | ||||||
| Additional paid in capital | 410,500 | 408,844 | ||||||
| Accumulated other comprehensive loss | (17,718 | ) | (21,695 | ) | ||||
| Accumulated deficit | (207,793 | ) | (190,287 | ) | ||||
| Total shareholders’ equity | 185,171 | 197,044 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 207,635 | $ | 220,358 | ||||
ACHILLES THERAPEUTICS PLC
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(in thousands, except share and per share amounts)
(expressed in U.S. Dollars, unless otherwise stated)
| Three Months Ended March 31, | ||||||||
| 2023 | 2022 | |||||||
| OPERATING EXPENSES: | ||||||||
| Research and development | $ | 13,868 | $ | 13,014 | ||||
| General and administrative | 4,685 | 5,955 | ||||||
| Total operating expenses | 18,553 | 18,969 | ||||||
| Loss from operations | (18,553 | ) | (18,969 | ) | ||||
| OTHER INCOME, NET: | ||||||||
| Other income (expense) | 1,091 | 1,629 | ||||||
| Total other income, net | 1,091 | 1,629 | ||||||
| Loss before provision for income taxes | (17,462 | ) | (17,340 | ) | ||||
| Provision for income taxes | (44 | ) | (15 | ) | ||||
| Net loss | (17,506 | ) | (17,355 | ) | ||||
| Other comprehensive income: | ||||||||
| Foreign exchange translation adjustment | 3,977 | (7,677 | ) | |||||
| Comprehensive loss | $ | (13,529 | ) | $ | (25,032 | ) | ||
| Net loss per share attributable to ordinary shareholders—basic and diluted | $ | (0.44 | ) | $ | (0.45 | ) | ||
| Weighted average ordinary shares outstanding—basic and diluted | 39,732,186 | 38,891,822 | ||||||
| Last Trade: | US$1.06 |
| Daily Change: | -0.01 -0.93 |
| Daily Volume: | 533,075 |
| Market Cap: | US$43.560M |
November 14, 2024 August 14, 2024 May 08, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
